Capital Investment Services of America Inc. Sells 1,961 Shares of ResMed Inc. (NYSE:RMD)

Capital Investment Services of America Inc. decreased its holdings in ResMed Inc. (NYSE:RMD - Free Report) by 1.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 118,427 shares of the medical equipment provider's stock after selling 1,961 shares during the quarter. ResMed accounts for approximately 2.6% of Capital Investment Services of America Inc.'s holdings, making the stock its 16th biggest position. Capital Investment Services of America Inc. owned approximately 0.08% of ResMed worth $27,083,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in RMD. True Wealth Design LLC lifted its position in ResMed by 2,200.0% during the third quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider's stock valued at $28,000 after purchasing an additional 110 shares during the period. Ashton Thomas Securities LLC purchased a new stake in ResMed during the 3rd quarter valued at $34,000. Rosenberg Matthew Hamilton bought a new position in shares of ResMed during the 4th quarter valued at $54,000. Capital Performance Advisors LLP bought a new stake in shares of ResMed in the third quarter worth $60,000. Finally, Venturi Wealth Management LLC increased its position in ResMed by 55.7% during the third quarter. Venturi Wealth Management LLC now owns 341 shares of the medical equipment provider's stock valued at $83,000 after acquiring an additional 122 shares during the last quarter. Hedge funds and other institutional investors own 54.98% of the company's stock.

ResMed Price Performance

RMD traded down $0.34 during trading on Friday, hitting $236.84. 830,561 shares of the company traded hands, compared to its average volume of 1,059,213. The company has a current ratio of 3.33, a quick ratio of 2.29 and a debt-to-equity ratio of 0.13. The company has a market cap of $34.78 billion, a PE ratio of 27.96, a P/E/G ratio of 1.57 and a beta of 0.70. The stock's 50-day simple moving average is $239.18 and its two-hundred day simple moving average is $237.59. ResMed Inc. has a 1 year low of $170.56 and a 1 year high of $263.05.

ResMed (NYSE:RMD - Get Free Report) last issued its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share for the quarter, beating analysts' consensus estimates of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%. As a group, sell-side analysts anticipate that ResMed Inc. will post 9.44 earnings per share for the current fiscal year.

ResMed Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th will be issued a dividend of $0.53 per share. The ex-dividend date of this dividend is Thursday, February 13th. This represents a $2.12 annualized dividend and a dividend yield of 0.90%. ResMed's dividend payout ratio (DPR) is 25.03%.

Wall Street Analyst Weigh In

RMD has been the subject of a number of research reports. Stifel Nicolaus started coverage on shares of ResMed in a report on Friday, December 13th. They set a "hold" rating and a $250.00 target price for the company. Royal Bank of Canada lifted their target price on ResMed from $224.00 to $232.00 and gave the company a "sector perform" rating in a research report on Friday, October 25th. The Goldman Sachs Group started coverage on ResMed in a research report on Thursday, January 16th. They issued a "buy" rating for the company. StockNews.com upgraded ResMed from a "hold" rating to a "buy" rating in a research note on Tuesday, October 15th. Finally, Robert W. Baird raised their target price on shares of ResMed from $280.00 to $283.00 and gave the stock an "outperform" rating in a research note on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $244.73.

Insider Activity

In other news, Director Peter C. Farrell sold 2,000 shares of the firm's stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $242.11, for a total value of $484,220.00. Following the completion of the sale, the director now directly owns 77,218 shares of the company's stock, valued at $18,695,249.98. This trade represents a 2.52 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Witte Jan De sold 796 shares of the business's stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $248.81, for a total value of $198,052.76. Following the transaction, the director now directly owns 6,723 shares in the company, valued at approximately $1,672,749.63. This represents a 10.59 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,094 shares of company stock worth $2,704,941. 0.71% of the stock is currently owned by insiders.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.